REV Group, Inc. (NYSE: REVG) exceeded expectations in its third-quarter fiscal 2023 earnings report, posting adjusted earnings of $0.35 per share compared to the consensus EPS estimate of $0.23. The company also outperformed in terms of quarterly sales, reporting $680.00 million, surpassing analysts' expectations of $627.16 million in revenue.

As a result of this strong performance, REV Group is revising its full-year fiscal 2023 revenue guidance upward to a range of $2.55 billion to $2.60 billion, up from the previous guidance range of $2.45 billion to $2.55 billion. This new guidance is better than the consensus estimate of $2.53 billion in revenue for the period.

$REVG is trading at $13.99 in pre-market, reflecting a substantial increase of $1.11 or 8.62%.

In other news, Needham has initiated coverage on Immunocore Holdings plc (Nasdaq: IMCR), a leading biotechnology company specializing in cutting-edge immunotherapy solutions, with a Buy rating and a price target of $75.

Despite closing at $54.02 on Tuesday, the assigned price target implies a potential upside of $20.98 or approximately 38.86% for $IMCR, according to the brokerage firm's view.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)